Merck Serono's oral MS drug approved in Russia, its first market
This article was originally published in Scrip
Executive Summary
Merck's Serono's oral relapsing-remitting multiple sclerosis (RRMS) drug Cladribine Tablets has been approved in the Russian Federation, its first market. It is expected to be made available in early 2011 under the trade name Movectro.